[30P-am] Modalities, biomolecules, biologics/Targeting/Pharmacologically active compounds (incl. metabolites)/Structure-activity relationship

[30P-am098] Survey and Consideration for Evaluation of Plasma/Serum Protein Binding of Globally-Approved Oligonucleotide Therapeutics

○Kei Fukuhara^1,2, Mika Miyoshi^1,3, Naomi Tamura^1,4, Yutaka Niwayama^1,5, Yasufumi Fukano^1,6, Shunji Imai^1,7 (1. Japan Pharmaceutical Manufacturers Association, 2. Pfizer R&D Japan, 3. Sanwa Kagaku Kenkyusho, 4. Shionogi, 5. Kyorin Pharmaceutical, 6. Nippon Boehringer Ingelheim, 7. Nippon Shinyaku)